Assembly Biosciences Investor Relations Material

Assembly Biosciences, Inc. is a biopharmaceutical company focused on developing small molecule antiviral therapeutics. It is primarily engaged in the discovery and development of treatments targeting hepatitis B virus (HBV) and hepatitis delta virus (HDV), including a portfolio of HBV core inhibitors and other novel antiviral compounds aimed at managing chronic infections. Additionally, the company explores therapies for herpesviruses, with programs advancing long-acting inhibitors and other non-nucleoside polymerase inhibitors intended for transplant-associated infections and other serious disease conditions. Assembly Biosciences is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.